S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

R. Andrew Shippy; Douglas Mendez; Kristina Jones; Irene Cergnul; Stephen E. Karpiak

doi:10.1186/1471-244X-4-38

S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

R. Andrew Shippy, Douglas Mendez, Kristina Jones, Irene Cergnul, Stephen E. Karpiak

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

Original language	English (US)
Article number	38
Journal	BMC Psychiatry
Volume	4
DOIs	https://doi.org/10.1186/1471-244X-4-38
State	Published - Nov 11 2004
Externally published	Yes

ASJC Scopus subject areas

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1471-244X-4-38

Cite this

@article{04af2065c35c447b8f6d016a40522d04,

title = "S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS",

abstract = "Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another {"}pill{"} or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.",

author = "Shippy, {R. Andrew} and Douglas Mendez and Kristina Jones and Irene Cergnul and Karpiak, {Stephen E.}",

year = "2004",

month = nov,

day = "11",

doi = "10.1186/1471-244X-4-38",

language = "English (US)",

volume = "4",

journal = "BMC Psychiatry",

issn = "1471-244X",

publisher = "BioMed Central",

}

TY - JOUR

T1 - S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

AU - Shippy, R. Andrew

AU - Mendez, Douglas

AU - Jones, Kristina

AU - Cergnul, Irene

AU - Karpiak, Stephen E.

PY - 2004/11/11

Y1 - 2004/11/11

N2 - Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

AB - Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

UR - http://www.scopus.com/inward/record.url?scp=12944262127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944262127&partnerID=8YFLogxK

U2 - 10.1186/1471-244X-4-38

DO - 10.1186/1471-244X-4-38

M3 - Article

C2 - 15538952

AN - SCOPUS:12944262127

SN - 1471-244X

VL - 4

JO - BMC Psychiatry

JF - BMC Psychiatry

M1 - 38

ER -

S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this